Key result
Prior left atrial appendage occlusion was associated with a lower rate of disabling cerebrovascular events at 12 months compared to warfarin therapy.
Why the study?
Does percutaneous left atrial appendage occlusion reduce neurological disability after ischemic cerebrovascular events in patients with nonvalvular atrial fibrillation compared to warfarin?
Cohort (n=92)
Yes
Does percutaneous left atrial appendage occlusion reduce neurological disability after ischemic cerebrovascular events in patients with nonvalvular atrial fibrillation compared to warfarin?
Ischemic cerebrovascular events occurring after percutaneous LAA occlusion are associated with significantly less long-term neurological disability compared to events occurring in patients treated with warfarin.
Answers are grounded in this paper and cite their sources.
LAAO-associated events may cause less long-term disability than warfarin events; hypothesis-generating and requires randomized confirmation.
OBJECTIVES: This study sought to investigate neurological disability after ischemic cerebrovascular events in patients treated with left atrial appendage (LAA) occlusion compared with those on warfarin. BACKGROUND: Prior studies demonstrated that cerebrovascular events after LAA occlusion in patients with nonvalvular atrial fibrillation (NVAF) is largely nondisabling. METHODS: From the 1,189 patients in the Korean LAA Occlusion and European Amplatzer Cardiac Plug Multi-Center Registry, 24 patients who experienced ischemic cerebrovascular events after LAA occlusion were enrolled. The neurological outcomes were compared with those in 68 patients who experienced an ischemic cerebrovascular event while on warfarin (Yonsei Stroke Registry). A modified Rankin scale (mRS) score of 3-6 categorized the cerebrovascular event as disabling. The mRS at discharge and at 3 and 12 months postcerebrovascular event in the two groups was compared. RESULTS: The percentages of disabling cerebrovascular events were 37.5% and 58.8% at discharge (P = 0.07), 20.8% and 42.6% at 3 months (P = 0.08), and 12.5% and 39.7% at 12 months (P = 0.02) in the LAA occlusion and warfarin groups, respectively. The mRS was significantly lower in the LAA occlusion group at discharge and at 3 months (P < 0.01) and 12 months (P < 0.01) postcerebrovascular event despite no significant difference in mRS before cerebrovascular events (P = 0.98). Patients in the LAA occlusion group demonstrated a significant reduction in mRS between discharge and 12 months (P < 0.01), unlike patients in the warfarin group (P = 0.10). CONCLUSIONS: Ischemic cerebrovascular events in patients who previously underwent percutaneous LAA occlusion for NVAF were more favorable than in patients on warfarin.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2018) conducted a cohort in Ischemic cerebrovascular events in nonvalvular atrial fibrillation (n=92). Percutaneous left atrial appendage occlusion vs. Warfarin was evaluated on Disabling cerebrovascular event (modified Rankin scale score 3-6) at 12 months (p=0.02). Prior left atrial appendage occlusion was associated with a lower rate of disabling cerebrovascular events at 12 months compared to warfarin therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: